保存年轻乳腺癌患者生育能力的相关临床问题

doi:10.3760/cma.j.issn.1673-422X.2014.02.010

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (2): 110-112.doi: 10.3760/cma.j.issn.1673-422X.2014.02.010

保存年轻乳腺癌患者生育能力的相关临床问题

段佳君

650118 昆明医科大学附属第三医院云南省肿瘤医院乳腺病科

收稿日期:2013-09-13 修回日期:2013-12-08 出版日期:2014-02-08 发布日期:2014-01-26
通讯作者: 段佳君, E-mail:duanjiajun58@gmail.com E-mail:duanjiajun58@gmail.com

Fertility preservation of young patients with breast cancer

Duan Jiajun

Department of Breast, Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming 650118, China

Received:2013-09-13 Revised:2013-12-08 Online:2014-02-08 Published:2014-01-26
Contact: Duan Jiajun E-mail:duanjiajun58@gmail.com

摘要/Abstract

摘要： 保存年轻乳腺癌患者的生育能力是影响患者生活质量的重要问题，但治疗后生育对患者远期生存有影响，因而需合理选择妊娠时机。乳腺癌系统治疗下生育能力会遭受各种损伤，现阶段保护生育能力的措施有应用促性腺激素释放激素类似物、胚胎冷冻保存、卵母细胞冷冻保存和卵巢组织冷冻保存。

关键词: 乳腺肿瘤, 生育力

Abstract: It is an important problem to preserve fertility of young patients with breast cancer, which infects the life quality of patients. But fertility after treatment has an impact on longterm survival, so the appropriate pregnancy time should be chosen carefully. The fertility of breast canser patient suffers all kinds of damage after systemic therapy. At the present stage, the measures of fertility protection include application of gonadotropinreleasing hormone analogue, embryo cryopreservation, oocyte cryopreservation and ovarian tissue cryopreservation.

Key words: Breast neoplasms, Fertility

段佳君. 保存年轻乳腺癌患者生育能力的相关临床问题[J]. 国际肿瘤学杂志, 2014, 41(2): 110-112.

Duan Jiajun. Fertility preservation of young patients with breast cancer[J]. Journal of International Oncology, 2014, 41(2): 110-112.

参考文献

［1］ Peate M, Meiser B, Cheah BC, et al. Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertilityrelated decision aid in young women with earlystage breast cancer［J］. Br J Cancer， 2012， 106 (6): 1053-1061. ［2］ Hill KA, Nadler T, Mandel R， et al. Experience of young women diagnosed with breast cancer who undergo fertility preservation consultation［J］. Clin Breast Cancer, 2012， 12(2): 127-132. ［3］ Corney RH, Swinglehurst AJ. Young childless women with breast cancer in the UK: a qualitative study of their fertilityrelated experiences, options, and the information given by health professionals［J］. Psychooncology， 2013， In press. ［4］ Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer［J］. N Engl J Med, 2010， 362(22): 2053-2065. ［5］ Kroman N, Jensen MB, Wohlfahrt J, et al. Pregnancy after treatment of breast cancer—a populationbased study on behalf of Danish Breast Cancer Cooperative Group［J］. Acta Oncol, 2008, 47(4): 545-549. ［6］ Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a metaanalysis of 14 studies［J］. Eur J Cancer, 2011， 47(1): 7483. ［7］ Largillier R, Savignoni A, Gligorov J, et al. Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged< 35 years: a CET(N)A Working Group analysis［J］. Cancer, 2009， 115(22): 5155-5165. ［8］ Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after longterm amenorrhea after breast cancer treatment: a prospective study［J］. Cancer, 2010， 116(3): 3102-3111. ［9］ Christinat A, Pagani O. Fertility after breast cancer［J］. Maturitas， 2012， 73(3): 191-196. ［10］ Christinat A, Di Lascio S, Pagani O. Hormonal therapies in young breast cancer patients: when, what and for how long? ［J］. J Thorac Dis， 2013， 5 Suppl 1: S36-46. ［11］ Oktay K, Türküoˇglu I, RodriguezWallberg KA, et al. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation［J］. Reprod Biomed Online， 2010， 20(6): 783-788. ［12］ Das M, Shehata F, Son WY, et al. Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy［J］. Hum Reprod， 2012， 27(8): 2509-2514. ［13］ Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine［J］. Stem Cell, 2011， 29(4): 570-575. ［14］ Pagani O, Partridge A, Korde L, et al. Pregnancy after breast cancer: if you wish, ma′am［J］. Breast Cancer Res Treat， 2011， 129(2): 309-317.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.

保存年轻乳腺癌患者生育能力的相关临床问题

Fertility preservation of young patients with breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价